These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 23768706)

  • 1. Spontaneous hemoperitoneum in recurrent jejunal gastrointestinal stromal tumor after imatinib therapy.
    Yin TC; Fan WC; Huang CJ; Hsieh JS
    Kaohsiung J Med Sci; 2013 Jul; 29(7):402-3. PubMed ID: 23768706
    [No Abstract]   [Full Text] [Related]  

  • 2. [Two cases of primary unresectable and/or recurrent gastrointestinal stromal tumors of small intestine presenting hemoperitoneum caused by administration of imatinib mesylate].
    Yokoyama A; Dairaku N; Kusano M; Koshita S; Shimada N; Yamagiwa T; Kojima Y; Ojima T; Ikeya S; Nakayama H; Sugai Y; Hiwatashi N; Asano S
    Nihon Shokakibyo Gakkai Zasshi; 2008 Nov; 105(11):1619-26. PubMed ID: 18987447
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Imatinib adjuvant therapy after surgical excision of gastrointestinal stromal tumour.
    Prescrire Int; 2011 Feb; 20(113):38. PubMed ID: 21488587
    [No Abstract]   [Full Text] [Related]  

  • 4. Facial hyperpigmentation during imatinib therapy for gastrointestinal stromal tumor.
    Hamza I; Gaies E; Kastalli S; Daghfous R; El Aidli S
    Therapie; 2014; 69(3):245-7. PubMed ID: 24934821
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lichenoid drug eruption with hyperpigmentation caused by imatinib mesylate.
    Kagimoto Y; Mizuashi M; Kikuchi K; Aiba S
    Int J Dermatol; 2014 Mar; 53(3):e161-2. PubMed ID: 23786260
    [No Abstract]   [Full Text] [Related]  

  • 6. Improved outcome with multimodal treatment and imatinib rechallenge in advanced GIST.
    Gasparotto D; Miolo G; Torrisi E; Canzonieri V; Bertola G; Libra M; Marzotto A; Maestro R; Buonadonna A
    Int J Colorectal Dis; 2014 May; 29(5):639-40. PubMed ID: 24525699
    [No Abstract]   [Full Text] [Related]  

  • 7. Intolerance to imatinib in gastrointestinal stromal tumors: a case report and a review of literature.
    Akasbi Y; Arifi S; Brahmi SA; El Mrabet FZ; Mellas N; Mernisi FZ; El Mesbahi O
    J Gastrointest Cancer; 2014 Dec; 45 Suppl 1():71-3. PubMed ID: 24006243
    [No Abstract]   [Full Text] [Related]  

  • 8. Osteonecrosis of the tibia associated with imatinib in metastatic GI stromal tumor.
    Yeh CN; Fu CJ; Yen TC; Chiang KC; Jan YY; Chen MF
    J Clin Oncol; 2013 Jun; 31(16):e248-50. PubMed ID: 23569321
    [No Abstract]   [Full Text] [Related]  

  • 9. Imatinib induced pyoderma gangrenosum.
    Pinato DJ; Sharma R
    J Postgrad Med; 2013; 59(3):244-5. PubMed ID: 24029213
    [No Abstract]   [Full Text] [Related]  

  • 10. Haemoperitoneum as an indicator of GIST.
    de Juan Ferré A; Gutiérrez L; Garicano F; Malaxetxebarria S; Fernández F
    Anticancer Drugs; 2012 Jun; 23 Suppl():S10-2. PubMed ID: 22739665
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hair graying and loss induced by imatinib mesylate.
    Yun SK; Song KH; Hwang SR; Kim HU; Lee NR; Park J
    J Dermatol; 2014 Jan; 41(1):107-8. PubMed ID: 24354806
    [No Abstract]   [Full Text] [Related]  

  • 12. Duodenal perforation caused by imatinib mesylate during adjuvant treatment of gastric stromal tumor: Case report.
    Liao MJ; Wu YQ; Lu T; Yang QB
    Int J Clin Pharmacol Ther; 2021 Jun; 59(6):467-470. PubMed ID: 33605877
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multiple bowel perforations complicating imatinib treatment for advanced gastrointestinal stromal tumor.
    Chiarugi M; Galatioto C; Lippolis PV; Seccia M
    J Am Coll Surg; 2008 Feb; 206(2):386-7. PubMed ID: 18222396
    [No Abstract]   [Full Text] [Related]  

  • 14. Soft tissue calcification secondary to imatinib mesylate in a patient with gastrointestinal stromal tumor.
    Enck RE; Abushahin F; Bossaer JB
    J Oncol Pharm Pract; 2014 Apr; 20(2):137-40. PubMed ID: 23676509
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lymphomatoid granulomatosis in a patient previously diagnosed with a gastrointestinal stromal tumour and treated with imatinib.
    Salmons N; Gregg RJ; Pallalau A; Woolhouse I; Geh I; Tanière P
    J Clin Pathol; 2007 Feb; 60(2):199-201. PubMed ID: 17264244
    [No Abstract]   [Full Text] [Related]  

  • 16. Long-term efficacy of imatinib for treatment of metastatic GIST.
    Patel S
    Cancer Chemother Pharmacol; 2013 Aug; 72(2):277-86. PubMed ID: 23503753
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatitis B viral reactivation secondary to imatinib treatment in a patient with gastrointestinal stromal tumor.
    Walker EJ; Simko JP; Ko AH
    Anticancer Res; 2014 Jul; 34(7):3629-34. PubMed ID: 24982379
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoodjuvant imatinib mesylate for advanced primary and metastactic/recurrent gastro-intestinal stromal tumour (GIST).
    Das D; Ganguly S; Deb AR; Aich RK
    J Indian Med Assoc; 2013 Jan; 111(1):21-3. PubMed ID: 24000503
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety evaluation of two doses of imatinib for the treatment of advanced gastrointestinal stromal tumors (GISTs).
    Yang P; Chen B; Zhou Y; Wu XT
    Clin Res Hepatol Gastroenterol; 2012 Oct; 36(5):484-90. PubMed ID: 22889747
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transient respiratory failure possibly associated to imatinib.
    Lengerke C; Brümmendorf T; Herrlinger U; Horger M; Kanz L; Hartmann JT
    Invest New Drugs; 2005 Mar; 23(2):137-8. PubMed ID: 15744589
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.